OceanBase Records Over 100% Increase in Number of Customers
13.1.2022 09:59:00 EET | Business Wire | Press release
OceanBase，an enterprise-level distributed relational database provider, announced during this year’s Distributed Database Developer Conference that its database products have been adopted by over 400 customers, which equals to a year-on-year increase of over 100% from 2020 to 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112006074/en/
Yang Bing, CEO of OceanBase, speaking during the Distributed Database Developer Conference on January 6, 2022. (Photo: Business Wire)
OceanBase, an Ant Group company, has seen its business expanding rapidly during the past year. So far, a quarter of the top 200 financial institutions in China have chosen OceanBase as a preferred technology provider to upgrade their core IT systems. OceanBase is also serving customers from non-financial service industries such as energy, telecommunication, and transportation. Customers from these sectors contribute to about 35 percent of OceanBase's total revenue.
Meanwhile, OceanBase is exploring the Small and Medium Enterprises (SMEs) market, which now accounts for near 70 percent of its customer base. Regional banks, insurers, security brokers, and wealth management companies have also been partnering with OceanBase and see it as one of the leading database technology providers.
"With its 'product-driven growth' business model, OceanBase aims to make database system management and operation easier and more seamless, " said Yang Bing, CEO of OceanBase. "We look forward to working with partners, customers, developers, and other industry participants to accelerate the development of database technology with continuous technology and product innovations."
"The distributed database is able to handle computing tasks across different nodes, bringing great advantages to dealing with large throughput and group computing," said Michael “Monty” Widenius, founder at MariaDB Foundation and the main author of the original version of the open-source MySQL in the conference. As for open-sourced database products like MariaDB and OceanBase, he commented, “Products and communities will maintain their vitality when they attract tens of millions of users while building healthy businesses."
The rapid development of the internet industry is accelerating the technology innovations of distributed databases that naturally have the ability to expand on a large scale. According to a recent report released by market intelligence provider Gartner, with advanced features including high availability, high scalability, multimodal implementation, supports of hybrid workloads and high compatibility, native distributed databases such as OceanBase are leading the trend of development in database technology, and the CAGR of the global market reaches 16.9 percent.
This year’s Distributed Database Developer Conference was co-hosted by CSDN, Mulan Open-source Community, Open Source China, and OceanBase on January 6. Other speakers participating in the conference included Bruce Momjian, co-founder and core team member of the PostgreSQL Global Development Group, Li Haixiang, the chief architect of Tencent's distributed database TDSQL, and Liu Song, VP of PingCAP.
About OceanBase
Launched in 2010, OceanBase is an enterprise-level distributed relational database developed by Ant Group. OceanBase’s benefits over alternative solutions include strong data consistency, high availability, high performance, low cost, online scalability, and high compatibility with SQL standards and other mainstream relational databases. Its performance has been proven in many Alipay large-scale business scenarios, as well as at the annual 11.11 Global Shopping Festival. In May 2020, OceanBase set the world record for online transaction processing performance, with 707 million transactions per minute in a TPC-C benchmark test. OceanBase was officially registered as a separate company in June 2020.
To learn more, please visit: https://www.oceanbase.com/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112006074/en/
Contact information
Media Inquires
Vick Li Wei
OceanBase
Vick.lw@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom